Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog®
| Autor: | Jeppe Sturis, Natalie Kurtz, Magnus Ekelund, Gayane Voskanyan, Robert A. Vigersky, Benyamin Grosman, Ohad Cohen, Neha J. Parikh, Anirban Roy, Di Wu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Type 1 diabetes
business.industry Insulin medicine.medical_treatment Health Informatics Hypoglycemia medicine.disease Artificial pancreas 030218 nuclear medicine & medical imaging Computer Science Applications Insulin aspart 03 medical and health sciences 0302 clinical medicine Postprandial Virtual patient Anesthesia medicine business 030217 neurology & neurosurgery Software Glycemic medicine.drug |
| Zdroj: | Computer Methods and Programs in Biomedicine. 205:106087 |
| ISSN: | 0169-2607 |
| Popis: | Introduction Medtronic has developed a virtual patient simulator for modeling and predicting insulin therapy outcomes for people with type 1 diabetes (T1D). An enhanced simulator was created to estimate outcomes when using the MiniMedTM 670G system with standard NovoLog® (EU: NovoRapid, US: NovoLog) versus Fiasp ® by using clinical data. Methods Sixty-seven participants' PK profiles were generated per type of insulin (Total of 134 PK profiles). 7,485 virtual patients' PK measurements was matched with one of the 67 NovoLog® PK Tmax values. These 7,485 virtual patients were then simulated using the Medtronic MiniMed™ 670G algorithm following an in-silico protocol of 90 days: 14 days in open loop (Manual Mode) followed by 76 days in closed loop (Auto Mode). Simulation study was repeated with each NovoLog® PK profile being replaced by its corresponding Fiasp® PK profile in the same virtual patient. To validate our in-silico analysis, we compared the results of “actual” 19 “real life” patients from a clinical study Results Simulated overall and postprandial glycemic outcomes improved in all age groups with Fiasp®. The percentage of time in the euglycemic range increased by about ~2.2% with Fiasp®, in all age groups (p Conclusions The simulation studies indicate that using Fiasp® in place of NovoLog® with the MiniMedTM 670G system will significantly improve the time spent in the healthy, euglycemic range and reduce exposure to hyperglycemia and hypoglycemia in most patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect